PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
34.89%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
59.22%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
59.22%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
77.92%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
-37.27%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-272.88%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-313.33%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
10.47%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
-20.54%
Diluted share reduction needs verification. Benjamin Graham would examine sustainability.